Scynexis's Oral Ibrexafungerp Shows Potency Against Severe Fungal Infections
SCYNEXIS Inc (NASDAQ:SCYX) has announced interim data from its ongoing Phase 3 FURI and CARES studies of ibrexafungerp in severe fungal infections. FURI study included fungal infections patients who are either intolerant to standard antifungal therapy or experience refractory fungal infections despite treatment. The CARES study is evaluating oral ibrexafungerp in patients with…
Benzinga ·
Benzinga
